Targeted drugs for systemic therapy of lung cancer with brain metastases
Authors:
Open Access
- 22 December 2017
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (4) , 5459-5472
Abstract
Targeted drugs for systemic therapy of lung cancer with brain metastases Targeted drugs for systemic therapy of lung cancer with brain metastasesKeywords
This publication has 101 references indexed in Scilit:
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in CancerClinical Cancer Research, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice NetworkThe Oncologist, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysisBMC Cancer, 2009
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiationEuropean Journal of Cancer, 2002
- A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumorsJournal of Neuro-Oncology, 1994
- Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancerEuropean Journal of Cancer, 1993
- The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology groupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1980